When your product launches 5, 8 or 10 years from now, what do you intend the label to read? You cannot make any commercial claim if it is not scientifically proven and written in the label. As early as discovery and throughout development, entrepreneurs and startups would do well to keep their end-goal in mind.
What is the exact target population, indication and formulation? Which benefits, risks and tolerability concerns are acceptable? What are unique selling points compared to competitors? And who is going to pay?
During this session our speakers will discuss their views on the importance of ascertaining early how health interventions will potentially add value in the future marketplace. Developers need to consider all the stakeholders — Patients, Partners, Prescribers and Payers. Having a clear picture could help guide business decisions and business development opportunities.
Within the Janssen Pharmaceutical Companies of Johnson & Johnson the Target Product Profile (TPP) is the go-to document describing the end-goal. The TPP is a concise communication tool designed with the aim to demonstrate key value drivers and attributes of the intended product. Our speakers will discuss what this document looks like and how it could guide prioritization and decision making.
Throughout discovery and development, startups can work together with many partners such as investors, R&D partners and service providers. During a panel discussion we will hear from different stakeholders how the TPP could help startups and their collaborators stay focused and aligned.
Agenda
Please note: More speakers will be announced in due course
15:30 CEST Introduction by Johnson & Johnson Innovation
- Elena Fernandez-Kleinlein | Head of JLABS EMEA, Johnson & Johnson Innovation
15:35 CEST Developing a commercial strategy during discovery & early development
- Mark Hicken | Vice President European Strategy Organization, Janssen Pharmaceutica
15:55 CEST The Target Product Profile as your North Star
- Kati Vandermeulen | Senior Director Compound Development Team Leader, Janssen Pharmaceutica
16:15 CEST Panel Discussion
- Mark Hicken | Vice President European Strategy Organization, Janssen Pharmaceutica
- Kati Vandermeulen | Senior Director Compound Development Team Leader, Janssen Pharmaceutica
- Paul Soons | Early Development Expert, Janssen Pharmaceutica
- Koen Vanhoutte | Head of Small Molecules CMC, Janssen R&D
- Alain Vicari | CEO & Co-founder, Calypso Biotech
- Els Eerdekens | Project Management Therapeutic Area Lead (TAL) Vaccines & Global Public Health, Janssen R&D (Moderator)
16:45 CEST Audience Q&A
17:00 CEST End of Broadcast
Source: Johnson & Johson Innovation